Agenus Inc. (NASDAQ:AGEN) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Monday, July 24th.
Several other equities analysts have also issued reports on AGEN. Maxim Group reissued a “buy” rating and issued a $7.00 price target on shares of Agenus in a research note on Sunday, April 23rd. HC Wainwright set a $5.00 price target on Agenus and gave the company a “hold” rating in a research note on Saturday, May 6th. Zacks Investment Research raised Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Wednesday, July 5th. Finally, ValuEngine lowered Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.88.
Shares of Agenus (NASDAQ:AGEN) opened at 3.55 on Monday. Agenus has a one year low of $3.20 and a one year high of $7.49. The firm’s 50-day moving average is $4.30 and its 200 day moving average is $3.90. The firm’s market capitalization is $353.98 million.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. During the same period in the previous year, the firm earned ($0.33) earnings per share. The company’s revenue was down 36.1% compared to the same quarter last year. Equities research analysts predict that Agenus will post ($1.13) earnings per share for the current year.
Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC raised its position in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock worth $140,000 after buying an additional 23,689 shares during the last quarter. OxFORD Asset Management LLP purchased a new position in shares of Agenus during the second quarter worth $141,000. AQR Capital Management LLC purchased a new position in shares of Agenus during the fourth quarter worth $143,000. American International Group Inc. raised its stake in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,984 shares during the last quarter. Finally, Quotient Investors LLC raised its stake in Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock worth $177,000 after buying an additional 3,800 shares during the last quarter. 42.78% of the stock is currently owned by institutional investors.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
What are top analysts saying about Agenus Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agenus Inc. and related companies.